IL-12 modulatory compounds

1. A compound represented by formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

ring A is a ring system selected from the group consisting of:

wherein:

represents the point of attachment; and each ring system is optionally substituted with one or more substituents;

R 1 , for each occurrence, is independently, H or a lower alkyl;

R c , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl, haloalkyl, —OR k , —SR k , —NR h R j , hydroxylalkyl, alkylcarbonylalkyl, mercaptoalkyl, aminoalkyl, sulfonylalkyl, sulfonylaryl, or mercaptoalkoxy;

R g , for each occurrence, is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl, haloalkyl, —OR k , —SR k , —NR h R j , hydroxylalkyl, alkylcarbonylalkyl, mercaptoalkyl, aminoalkyl, sulfonylalkyl, sulfonylaryl, mercaptoalkoxy, —C(O)R c , —OC(O)R c , —SC(O)R c , —NRkC(O)R c , —C(S)R c , —OC(S)R c , —SC(S)R c , —NRkC(S)R c , —C(NR)R c , —OC(NR)R c , —SC(NR)R c , —NRkC(NR)R c , —S(O) 2 R c , —S(O)R c , —NR k S(O) 2 R c , —OS(O) 2 R c , —OP(O)R c R c , —P(O)R c R c , halo, cyano, nitro, nitroso, or azide;

R h and R j , for each occurrence, are independently H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, an optionally substituted heteroaryl; or R h and R j taken together with the nitrogen to which they are attached is an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, or an optionally substituted heteroaryl;

R k , for each occurrence, is independently H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, an optionally substituted aryl, or an optionally substituted heteroaryl;

ring E is optionally substituted with one to four substituents selected from a lower alkyl, a halo, an amino, a lower alkyl amino, a lower dialkyl amino, a cyano, a nitro, a lower haloalkyl, a hydroxyl, and a lower hydroxyalkyl;

V is CR g , Q and U are N;

X 1 is O;

X 2 is O;

Y 1 is O;

R 7 and R 8 , for each occurrence, are independently, H or a lower alkyl; and R 9 is H, an alkyl, an aralkyl, or an alkylcarbonyl;

q is 0, 1, 2, or 3.

2. The compound of claim 1 , wherein ring A is optionally substituted with from one to three substituents selected from the group consisting of a lower alkyl, a lower alkoxy, ═O, nitro, cyano, hydroxy, amino, lower alkyl amino, lower dialkyl amino, mercapto, lower alkyl sulfanyl, halo, or haloalkyl.

3. A compound selected from the group consisting of:

5-Methyl-3-{[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazono}-1,3-dihydro-indol-2-one;

N-(6-Methyl-chroman-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Methyl-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(Indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(Benzofuran-3-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(3-Methyl-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(4-Methyl-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(5-Methoxy-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Methoxy-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(Indan-2-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(3,4-Dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(Chroman-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Methoxy-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(7-Methoxy-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(7-Nitro-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Hydroxy-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(5,7-Dimethyl-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6,7-Dimethoxy-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(4-Methyl-3,4-dihydro-2H-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

1-Methyl-3-{[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazono}-1,3-dihydro-indol-2-one;

N-(4-Hydroxy-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(5-Hydroxy-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

3-{[6-Morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazono}-2,3-dihydro-benzofuran-6-ol;

N-(5-Hydroxy-3,4-dihydro-naphthalen-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Fluoro-chroman-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(5-Fluoro-indan-1-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6,7-Dihydro-5H-benzo[1,2,5]oxadiazol-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-[6-Morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-N′-(octahydro-naphthalen-1-ylidene)-hydrazine;

N-(4-tert-Butyl-cyclohexylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(2-Methyl-cyclohexylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-Cyclopentylidene-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-Bicyclo[2.2.1]hept-2-ylidene-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Chloro-thiochroman-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Chloro-1,1-dioxo-1λ 6 -thiochroman-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Methyl-chromen-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

N-(6-Chloro-chromen-4-ylidene)-N′-[6-morpholin-4-yl-2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine; and

N-(6,7-Dihydro-5H-benzofuran-4-ylidene)-N′-[6-morpholin-4-yl-2-(morpholin-4-yl-ethoxy)-pyrimidin-4-yl]-hydrazine;

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of claim 1 or 3 and a pharmaceutically acceptable carrier.